Form 4: Esperion CCO Granted Significant Equity and Options

Esperion Therapeutics' Chief Commercial Officer, John B. Harlow Jr., received an award of 424,536 common shares and 380,000 stock options.

Summary

• John B. Harlow Jr., Chief Commercial Officer of Esperion Therapeutics, Inc. (ESPR), reported an acquisition of securities.
• The transaction occurred on December 4, 2025.
• Harlow acquired 424,536 shares of Common Stock at a price of $0 per share, indicating an award.
• He also acquired 380,000 stock options with an exercise price of $3.79 per share.
• These awards will vest over a four-year period, with 25% vesting on December 15, 2026 (the one-year anniversary of the vesting commencement date of December 15, 2025), and the remainder vesting in equal quarterly installments over the subsequent three years.
• The stock options have an expiration date of December 4, 2035.
• Following these transactions, Harlow beneficially owns 424,536 shares of Common Stock and 380,000 stock options.

Sentiment

Score: 7

Explanation: The grant of significant equity and stock options to a key executive is generally positive as it aligns management's interests with shareholders and incentivizes long-term performance and retention.

Positives

• Significant equity grant to the Chief Commercial Officer, aligning management's interests with shareholders.
• The awards incentivize long-term performance and retention of a key executive.
• The vesting schedule promotes sustained commitment over a four-year period.

Risks

• The value of the granted common stock and stock options is subject to the future performance of Esperion Therapeutics' stock price.
• The vesting schedule means the full benefit of the awards is contingent on continued employment and company performance over four years.

Future Outlook

The equity and option awards, with their four-year vesting schedule, indicate a long-term commitment from the Chief Commercial Officer to the company's future performance and strategic objectives. The awards are designed to align his interests with the long-term growth and shareholder value creation of Esperion Therapeutics.

Industry Context

Executive compensation, particularly in the biotechnology and pharmaceutical sectors, frequently includes significant equity and stock option grants. These grants are a standard mechanism to attract, retain, and motivate key executives, aligning their financial incentives with the company's long-term success and shareholder returns, especially in industries with long development cycles and high-risk, high-reward profiles.

Comparison to Industry Standards

• The use of equity awards (common stock and stock options) for executive compensation is a standard practice across the biotech and pharmaceutical industries, comparable to compensation structures at companies like Amgen, Gilead Sciences, or Biogen.
• The four-year vesting schedule is typical for executive equity grants, designed to ensure long-term retention and performance alignment, similar to plans observed at peer companies.
• The specific size of the grant (424,536 shares and 380,000 options) would need to be benchmarked against the executive's role, company size, and performance metrics relative to industry peers to assess its competitiveness and appropriateness.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of executive incentives with shareholder value creation. The executive's personal wealth is now more directly tied to the company's stock performance.
• Employees: May signal confidence in the company's future and reinforce a culture of performance-based compensation.

Next Steps

• Continued vesting of the common stock and stock options over the next four years, commencing December 15, 2025.
• Potential exercise of stock options by John B. Harlow Jr. before their expiration date of December 4, 2035.

Key Dates

Keywords

Esperion Therapeutics, ESPR, Form 4, Insider Transaction, Equity Grant, Stock Options, Executive Compensation, Chief Commercial Officer, John B. Harlow Jr., Vesting